Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase 3 trial in patients with gastroesophageal adenocarcinoma.

Shitara, K; Özgüroğlu, MUSTAFA; Bang, Y-J; Di Bartolomeo, M; Mandalà, M; Ryu, M-H; Caglevic, C; Chung, H; Muro, K; Van Cutsem, E; Kobie, J; Cristescu, R; Aurora-Garg, D; Lu, J; Shih, C-S; Adelberg, D; Cao, Z; Fuchs, C

doi:10.1016/j.annonc.2021.05.803

Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase 3 trial in patients with gastroesophageal adenocarcinoma.

Shitara K., Özgüroğlu M., Bang Y., Di Bartolomeo M., Mandalà M., Ryu M., ...Daha Fazla

Annals of oncology : official journal of the European Society for Medical Oncology, cilt.32, ss.1127-1136, 2021 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 32
Basım Tarihi: 2021
Doi Numarası: 10.1016/j.annonc.2021.05.803
Dergi Adı: Annals of oncology : official journal of the European Society for Medical Oncology
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, CAB Abstracts, EMBASE, MEDLINE
Sayfa Sayıları: ss.1127-1136
Anahtar Kelimeler: pembrolizumab, chemotherapy, tumor mutational burden, gastroesophageal adenocarcinoma, gastric cancer, TUMOR MUTATIONAL BURDEN, TISSUE TMB TTMB, CTLA-4 BLOCKADE, PD-1 BLOCKADE, BENEFIT, PEMBRO, NSCLC, CHEMO
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Background: In the phase III KEYNOTE-061 trial (NCT02370498), pembrolizumab did not significantly improve overall survival versus paclitaxel as second-line therapy for gastric/gastroesophageal junction (GEJ) adenocarcinoma with programmed death-ligand 1 (PD-L1) combined positive score (CPS) >= 1 tumors. The association of tissue tumor mutational burden (tTMB) status and clinical outcomes was determined, including the relationship with CPS and microsatellite instability-high (MSI-H) status.